Preparation of New Glycerol-Based Dendrimers and Studies on Their Behavior toward Essential Oil Encapsulation

Two new families of glycerol-based dendrimers (glyceroladendrimers (GADs) and glyceroclickdendrimers (GCDs)) have been synthesized. Three generations have been isolated for each family with good yields and were fully analyzed. The encapsulation of essential oils (citronella and cinnamon) in GADs, GCDs, and also in previously described glycerodendrimers GD-PAMAMs and GD-PPIs has been studied by dynamic-headspace gas chromatography coupled to mass spectrometry. The retention rates obtained were from -35.8 to 26.65% for citronella essential oil and from 2.14 to 38.84% for the cinnamon essential oil. In addition, the best results were obtained with GD-PAMAMs and GD-PPIs of higher generation. The interaction study between essential oils or more precisely their major components have been performed through NMR spectroscopy (¹H NMR and DOSY NMR). No direct interactions between dendrimers and essential oils have been observed, but a surprising behavior of compression of the dendrimer in stable emulsions was observed. Indeed, the hydrodynamic radius of GD-PPI-3 has been reduced in the presence of cinnamon essential oil.

Dendrimers in the context of nanomedicine

Dendrimers are globular structures, presenting an initiator core, repetitive layers starting radially from the core and terminal groups on the surface, resembling tree architecture. These structures have been studied in many biological applications, as drug, DNA, RNA and proteins delivery, as well as imaging and radiocontrast agents. With reference to that, this review focused in providing examples of dendrimers used in nanomedicine. Although most studies emphasize cancer, there are others which reveal action in the neurosystem, reducing either neuroinflammation or protein aggregation. Dendrimers can carry bioactive compounds by covalent bond (dendrimer prodrug), or by ionic interaction or adsortion in the internal space of the nanostructure. Additionally, dendrimers can be associated with other polymers, as PEG (polyethylene glycol), and with targeting structures as aptamers, antibodies, folic acid and carbohydrates. Their products in preclinical/clinical trial and those in the market are also discussed, with a total of six derivatives in clinical trials and seven products available in the market.

Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine

Antisense oligonucleotide (AON)-based therapies concern the treatment for genetic disorders or infections such as a range of neurodegenerative and neuromuscular diseases and have shown benefits in animal models and patients. Nevertheless, successes in the clinic are still strongly limited by unfavorable biodistribution and poor cellular uptake of AONs. Dendrimer macromolecules are synthetically accessible and consist of a core with repeated iterations (named branches) surrounding this core, and on the periphery functional groups which can be modified for ligand attachment. The generations of these branched nanoparticles are based on the number of branches emanating from the core with layered architectures. Dendrimers show promise in several biomedical applications based on their tunable surface modifications allowing the adjustment of their in vivo behavior related to biocompatibility and pharmacokinetic parameters. Dendrimers can be used as nanocarriers of various types of drugs including AONs or nanodrugs. As nanocarriers, polycationic dendrimers can complex multiple negatively charged DNA oligonucleotides on their surface and form stable complexes to promote internalization into the cells based on a good cell membrane affinity. These nanocarriers complexing antisense oligonucleotides must be stable enough to reach the cellular target, but with adequate in vivo global clearance, and have good pharmacokinetic (PK) and pharmacodynamic (PD) profiles. This Review was designed to analyze the development of AONs carried by polycationic and polyanionic (few example) dendrimers. This Review strongly supports the idea that dendrimers, with adequate modulation of their terminal groups, could be used to carry AONs in cells.

Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1)

Dendrimers are highly branched, star-shaped macromolecules with nanometer-scale dimensions that can be readily modified with a range of functional groups, thus modifying their physicochemical and biological properties. In nanomedicine, dendrimers can be used as vectors for the targeted delivery strategy of a variety of biologically active agents or can be used as drug per se. In the future, it will be necessary to designate and develop 'safe' dendrimers, which is currently a crucial concern. Here, we analyze the key in vitro physicochemical parameters to be considered for preclinical evaluation of biomedical dendrimers.